Biosimilar User Fees Would Be Same As BLAs, Only Earlier

FDA's proposed biosimilar product development fee would be charged upon IND submission, but subtracted from marketing application fee.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet